AstraZeneca

Threadneedle's Richard Colwell is adding more to stocks including Centrica and GlaxoSmithKline as he seeks contrarian equity income plays for the months ahead.

Neptune Investment Management's Mark Martin has overhauled the £66m UK Opportunities fund since taking over as lead manager, turning it into a higher conviction portfolio with fewer positions.

Embattled supermarket Tesco has suffered a further blow in the form of an investigation by the industry regulator into its treatment of suppliers.

Managing the low inflation challenge

Nick Kirrage has begun adding supermarkets to the £1.5bn Schroder Income fund he co-manages with Kevin Murphy, expecting a significant boost to dividends in the long term.

Shares in UK-listed pharmaceutical giants Shire and AstraZeneca have fallen sharply this morning, after the US Treasury introduced a new law to curb tax avoidance by US companies which buy overseas rivals.

UK

MERGERS AND ACQUISITIONS

The dangers of playing the momentum game

Neil Woodford is running his largest allocation to overseas stocks since 2013 as he begins management of his new UK equity income fund.